Why the study?
Recommended bivalirudin dosages in clinical guidelines may not be appropriate for East Asian populations, highlighting the need to evaluate a lower regimen in high-risk bleeding patients with ACS undergoing elective PCI.
Does a low bivalirudin regimen improve net adverse clinical events at 30 days in high-risk bleeding patients with ACS undergoing elective PCI compared to a standard regimen?
Does a low bivalirudin regimen improve net adverse clinical events at 30 days in high-risk bleeding patients with ACS undergoing elective PCI compared to a standard regimen?
This study protocol describes a randomized trial to determine if a low-dose bivalirudin regimen is safe and effective for East Asian ACS patients at high bleeding risk undergoing elective PCI.
Answers are grounded in this paper and cite their sources.
Protocol for RCT of low-dose bivalirudin in high-bleeding-risk East Asian ACS patients; leaves open net clinical benefit versus standard regimen.
BACKGROUND: Bleeding complications associated with anticoagulant therapy should receive more attention in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI), especially in those considered at high-risk bleeding. The recommended dosage of bivalirudin in clinical guidelines may not be appropriate for East Asian populations. We are performing a trial to investigate the efficacy and safety of a low bivalirudin regimen without prolonging infusion in high-risk bleeding patients with ACS undergoing elective PCI. METHODS: The study is a prospective, open-label, randomized controlled, non-inferiority trial. A total of 2510 patients will be enrolled and randomly (1,1) allocated to either receive the low (80 % of the standard dose) or standard bivalirudin regimen without prolonging the infusion after PCI. The primary endpoint is net adverse clinical events (NACE) at 30 days, which is a composite of major adverse cardiovascular and cerebrovascular events (MACCE, including all-cause death, repeat revascularization, stroke, nonfatal myocardial infarction, and stent thrombosis) and any bleeding events defined by the Bleeding Academic Research Consortium (BARC). CONCLUSIONS: This proposed study is the first randomized controlled trial to evaluate the efficacy and safety of a low versus standard bivalirudin regimen during elective PCI in high-risk bleeding patients with ACS. The results may help achieve dose optimization for the use of perioperative bivalirudin in high-risk bleeding ACS patients undergoing elective PCI. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2200064363. Registered on October 4, 2022.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: